Martin Fassnacht

Martin Fassnacht

Auto-generated profile, based on publicly available information

Martin Fassnacht

Comprehensive Cancer Center Mainfranken (M.F.), University of Würzburg, 97252 Würzburg, Germany 10 and Department of Internal Medicine (M.F.), Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, 80337 Munich, Germany

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
TKT. M. Kerkhofs
T. M. Kerkhofs
EBE. Baudin
E. Baudin
Massimo TerzoloMassimo Terzolo
Massimo Terzolo
BAB. Allolio
B. Allolio
RCR. Chadarevian
R. Chadarevian
MFM. Fassnacht
M. Fassnacht
Context: Mitotane is the only approved drug for treatment of adrenocortical carcinoma. Its pharmacokinetic properties are not fully elucidated and different dosing regimens have never been compared head to head. Objective: The objective of the study was to investigate the relationship between mitotane dose and plasma concentration comparing two dosing regimens. Design/Setting: This was a prospective, open-label, multicenter trial of a predefined duration of 12 weeks. Patients/Interventions: Forty mitotane-naïve patients with metastatic adrenocortical carcinoma were assigned to a predefined low- or high-dose regimen by the local investigator. Thirty-two patients could be evaluated in detail. Main Outcome Measure: The difference in median mitotane plasma levels between both treatment groups was measured. Results: Despite a difference in mean cumulative dose (440 ± 142 g vs 272 ± 121 g), median maximum plasma levels were not significantly different between the two groups [high dose 14.3 mg/L (range 6.3–29.7, n = 20) vs 11.3 mg/L (range 5.5–20.0, n = 12), P = .235]. Ten of 20 patients on the high-dose regimen reached plasma concentrations of 14 mg/L or greater after 46 days (range 18–81 d) compared with 4 of 12 patients on the low-dose regimen after 55 days (range 46–74 d, P = .286). All patients who reached 14 mg/L at 12 weeks displayed a level of 4.1 mg/L or greater on day 33 (100% sensitivity). There were no significant differences in frequency and severity of adverse events. Among patients not receiving concomitant chemotherapy mitotane exposure was higher in the high-dose group: 1013 ± 494 mg/L · d vs 555 ± 168 mg/L · d (P = .080). Conclusions: The high-dose starting regimen resulted in neither significantly different mitotane levels nor a different rate of adverse events, but concomitant chemotherapy influenced these results. Thus, for mitotane monotherapy the high-dose approach is favorable, whereas for combination therapy a lower dose seems reasonable.

1 September 2001 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
MFMartin Fassnacht
Martin Fassnacht
BCBarbara Capeller
Barbara Capeller
WAWiebke Arlt
Wiebke Arlt
TSThomas Steck
Thomas Steck
BABruno Allolio
Bruno Allolio

1 December 2000 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MFM. Fassnacht
M. Fassnacht
SHStefanie Hahner
Stefanie Hahner
FBF. Beuschlein
F. Beuschlein
AKA. Klink
A. Klink
MRM. Reincke
M. Reincke
BAB. Allolio
B. Allolio

1 September 2002 in Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
MFM Fassnacht
M Fassnacht
AFA Franke
A Franke
ADA Dettling
A Dettling
SHStefanie Hahner
Stefanie Hahner
MZM Zink
M Zink
BAB Allolio
B Allolio
Bisphosphonates (BPs), specific inhibitors of osteoclasts, are well established in the management of skeletal metastases in breast cancer. Recent studies have suggested that these compounds may also directly influence tumor cell proliferation. As adrenocortical cancer frequently leads to bone metastases, we investigated the effects of clodronate (CLO) in the human adrenocortical cancer cell line NCI-H295 and in primary cultures of bovine adrenocortical cells. Both the non-amino BP CLO and the amino BP pamidronate (PAM) exhibited a dose-dependent antiproliferative effect in both cell types (cell viability in NCI-H295 cells: 100 microM CLO: 98+/-8%; 500 microM CLO 76+/-6%; 1000 microM CLO 53+/-2; 10 microM PAM 96+/-3%; 50 microM PAM 46+/-6%; 100 microM PAM 11+/-1% vs untreated control cells: 100+/-10%; P<0.01). FACS analysis in NCI-H295 cells treated with either CLO or PAM demonstrated both apoptotic and necrotic cell death. However, while during PAM treatment cell number and hormone secretion decreased in parallel, we observed specific impairment of steroidogenesis in the presence of CLO with a dose-dependent increase in the 17-OH-progesterone/cortisol ratio (100 microM CLO 134+/-30%; 500 microM CLO 284+/-10%; 1000 microM CLO 545+/-130% vs 100+/-20% in control cells; P<0.01). Further analysis in ACTH-stimulated bovine adrenal cells using stable isotope dilution/gas chromatography-mass spectrometry demonstrated CLO-induced inhibition of adrenal 21-hydroxylase (P450c21) activity leading to a dose-dependent increase in the 17-OH-progesterone/11-deoxycortisol ratio. In conclusion, we demonstrate a dose-dependent antiproliferative effect of CLO and PAM in adrenocortical cells. In addition, for the first time, we describe a suppressive effect of CLO on steroidogenesis via inhibition of adrenal 21-hydroxylase (P450c21) activity.

7 March 2013 in Experimental and Clinical Endocrinology & Diabetes
Verified
Journal Article
Closed access
FBF Beuschlein
F Beuschlein
JOJ Obracay
J Obracay
WSW Saeger
W Saeger
MPMartin Reincke Prof
Martin Reincke Prof
RLR Libe
R Libe
MFM Fassnacht
M Fassnacht
Purpose: Recurrence of adrenocortical cancer (ACC) even after complete resection is a common clinical problem. The aim of this study was the identification of histological parameters with potential prognostic value. Patients and methods: From the German ACC registry 318 patients with ENSAT stage I-III were identified with R0 resection for whom histological analysis was available. Histological markers were correlated with recurrence free and overall survival. As an independent validation cohort 250 patients from six European centers were utilized. Results: Within the German cohort, univariate analysis identified age at diagnosis, tumor size and lymph node positivity as markers with predictive value for recurrence free survival (RFS). Accordingly, ENSAT staging was also of significance (p = 0.02). Ki67 index provided the single best prognostic value for recurrence free survival (HR 1.042 per % increase for the German cohort and HR 1.024 for the validation cohort; p < 0.001) which was superior to markers evaluated for calculation of the Weiss score. Following multivariate analysis including age, tumor size and adjuvant mitotane treatment Ki67 index remained informative. Similar results were obtainable for overall survival (HR 1.051 per % increase for the German cohort and HR 1.023 for the validation cohort; p < 0.001). Conclusion: In conclusion, Ki67 was identified as the single most important prognostic marker for disease recurrence in ACC patients following R0 resection. Our findings will help to guide decisions on adjuvant therapy for this rare disease.

28 February 2006 in Experimental and Clinical Endocrinology & Diabetes
Verified
Journal Article
Closed access
MFM. Fassnacht
M. Fassnacht
SHS. Hahner
S. Hahner
BPB. Polat
B. Polat
AKA. C. Koschker
A. C. Koschker
WKW. Kenn
W. Kenn
BAB. Allolio
B. Allolio
Objective: Local tumor recurrence is common in adrenocortical carcinoma (ACC) and the most frequent cause for re-operation. Therefore, a concept for an adjuvant treatment is urgently needed. The role of radiotherapy in ACC has not been well defined and many authors consider radiotherapy as ineffective. However, two studies with a small number of patients (n=3 and n=4, resp.) have suggested adjuvant radiation as an effective treatment to prevent recurrence in ACC (1.2). Methods: We analyzed all patients from the German ACC Registry who have been treated by tumor bed radiation. Only patients treated with 40–54 Gy in an adjuvant setting (no macroscopic evidence for residual tumor after initial surgery) were included. 16 patients (stage I: 1, stage II: 9, stage III: 6) with median tumor diameter of 12.5±4.2cm were matched with 16 patients for stage, R-status, adjuvant mitotane treatment, tumor size, and age. Results: Local recurrence occurred in 2/16 patients in the radiation group and in 9/16 control patients (p<0.05). The probability to be free of local recurrence 5 years after surgery differed significantly (82% vs. 39%; p<0.05). However, in this small series overall survival was not significantly different between both groups (5-year survival: 46% in radiation group vs. 64% in controls; p=0.6). Acute adverse effects related to radiation therapy were mostly mild (gastrointestinal grade CTC I+II, erythma CTC I, and fatigue CTC II, wound healing CTC II in 10, 5, 4, and 1 patients, respectively). One patient developed a partial Budd-Chiari syndrome and 1 patient developed impaired renal function CTC I during follow up probably related to radiotherapy. Conclusion: These data from the largest series of ACC patients treated with adjuvant tumor bed radiation suggest that radiation therapy is effective in reducing the high rate of local recurrence in ACC. However, no impact on long-term survival was demonstrated in this small patient sample. 1) King et al. Cancer 1979 2) Magee et al. Clin Radiol 1987